<p>The Figure demonstrates cytotoxicity of CAR T cells generated from CLL patients (n = 3) against CD19+ Daudi before (A) and after co-culture with IL-2 (B) and autologous B cells (C). The cytotoxicity was normalized to CAR expression due to variation of expression. Current CAR expression at each specific time-point was used for normalization. Error bars represent SEM.</p
CAR-T cell therapy is the most advanced way to treat therapy resistant hematologic cancers, in parti...
CD19-targeting CAR T cells have shown potency in clinical trials targeting B cell leukemia. Although...
<p>T cells were transduced with m1928z and infused at increasing doses (noted on axes) into congenic...
<p>CAR expression on 2G (A, B) and 3G (C, D) T cells was evaluated by flow cytometry before and afte...
<p>Culture supernatants were collected 24h after stimulation at day 1 (start) and at endpoint (end)....
<p>(A) Expression of CD19RCD28 CAR on T cells day after electroporation (culture day 1) and after 28...
<p>(A) and (B) The specificity of anti-CD19/CD28 CAR in targeting CD19-positive tumor cells. Results...
T cells engineered with chimeric antigen receptor (CAR-T cells) are an effective treatment in patien...
CD19-targeting CAR T cells have shown potency in clinical trials targeting B cell leukemia. Although...
Supplementary Figure S13. CAR-T response to in vitro CD19 antigen stimulation</p
<p>(<b>a</b>) Expression of CARs (αerbB2-CD28ζ: 57.99±12.66, αerbB2-DAP10ζCD27: 66.38±22.90. N = 3± ...
Proliferation of CLL-1 CAR-T cells in response to CLL-1+ cells. Pair-matched CFSE-labeled CLL-1 CAR-...
Adoptive transfer of CD19-redirected chimeric antigen receptor (CAR) T cells has shown remarkable ac...
<p>Cytotoxicity against B-ALL cells after 4-h co-culture with NK cells previously co-cultured with K...
In recent years, adoptive cell therapy has gained a new perspective of application due to the develo...
CAR-T cell therapy is the most advanced way to treat therapy resistant hematologic cancers, in parti...
CD19-targeting CAR T cells have shown potency in clinical trials targeting B cell leukemia. Although...
<p>T cells were transduced with m1928z and infused at increasing doses (noted on axes) into congenic...
<p>CAR expression on 2G (A, B) and 3G (C, D) T cells was evaluated by flow cytometry before and afte...
<p>Culture supernatants were collected 24h after stimulation at day 1 (start) and at endpoint (end)....
<p>(A) Expression of CD19RCD28 CAR on T cells day after electroporation (culture day 1) and after 28...
<p>(A) and (B) The specificity of anti-CD19/CD28 CAR in targeting CD19-positive tumor cells. Results...
T cells engineered with chimeric antigen receptor (CAR-T cells) are an effective treatment in patien...
CD19-targeting CAR T cells have shown potency in clinical trials targeting B cell leukemia. Although...
Supplementary Figure S13. CAR-T response to in vitro CD19 antigen stimulation</p
<p>(<b>a</b>) Expression of CARs (αerbB2-CD28ζ: 57.99±12.66, αerbB2-DAP10ζCD27: 66.38±22.90. N = 3± ...
Proliferation of CLL-1 CAR-T cells in response to CLL-1+ cells. Pair-matched CFSE-labeled CLL-1 CAR-...
Adoptive transfer of CD19-redirected chimeric antigen receptor (CAR) T cells has shown remarkable ac...
<p>Cytotoxicity against B-ALL cells after 4-h co-culture with NK cells previously co-cultured with K...
In recent years, adoptive cell therapy has gained a new perspective of application due to the develo...
CAR-T cell therapy is the most advanced way to treat therapy resistant hematologic cancers, in parti...
CD19-targeting CAR T cells have shown potency in clinical trials targeting B cell leukemia. Although...
<p>T cells were transduced with m1928z and infused at increasing doses (noted on axes) into congenic...